New drug DFV890 aims to control bone marrow diseases in early trial
NCT ID NCT05552469
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 29 times
Summary
This early-phase study tests a new drug called DFV890 in about 62 adults with certain bone marrow diseases, including lower-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The main goals are to check the drug's safety, find the best dose, and see if it can reduce the need for blood transfusions. Participants will receive DFV890 and be closely monitored for side effects and disease response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Novartis Investigative Site
Grenoble, 38043, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, 40225, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Leipzig, Saxony, 04103, Germany
-
Novartis Investigative Site
Lübeck, 23538, Germany
-
Novartis Investigative Site
Hong Kong, 999999, Hong Kong
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Cardiff, CF14 4XW, United Kingdom
-
Novartis Investigative Site
London, SE5 9RS, United Kingdom
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Sidney Kimmel CCC At JH
Baltimore, Maryland, 21231, United States
-
Stanford Cancer Center
Stanford, California, 94305, United States
-
Univ of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
Vanderbilt University Medical Ctr
Nashville, Tennessee, 37232, United States
-
Weill Cornell Medicine NY-Presb
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.